Wenzhou Medical University
Clinical Trials
94
Trial Phases
5 Phases
Drug Approvals
0
Drug Approvals
No drug approvals found
This company may not have drug approvals in our database
Clinical Trials
Distribution across different clinical trial phases (53 trials with phase data)• Click on a phase to view related trials
Comparing Monofocal IOLs in Highly Myopic Cataract Patients
- Conditions
- Cataract
- First Posted Date
- 2025-04-02
- Last Posted Date
- 2025-04-02
- Lead Sponsor
- Wenzhou Medical University
- Target Recruit Count
- 60
- Registration Number
- NCT06905938
- Locations
- 🇨🇳
Ophthalmology and Optometry Hos, Hanzhou, zhejian, China
Visual Quality of Cataract Patients with High Myopia After Implantation of Different Intraocular Lenses
- Conditions
- Cataract
- First Posted Date
- 2025-03-24
- Last Posted Date
- 2025-03-24
- Lead Sponsor
- Wenzhou Medical University
- Target Recruit Count
- 62
- Registration Number
- NCT06892470
- Locations
- 🇨🇳
Ophthalmology and Optometry Hos, Hanzhou, zhejian, China
Using Psychophysics Methods to Investigate Sensory Dominance After Cataract Surgery
- Conditions
- Cataract
- First Posted Date
- 2024-12-27
- Last Posted Date
- 2024-12-27
- Lead Sponsor
- Wenzhou Medical University
- Target Recruit Count
- 96
- Registration Number
- NCT06751342
- Locations
- 🇨🇳
Ophthalmology and Optometry Hospital, Wenzhou, Wenzhou, Zhejiang, China
Comparison of the Effect of Capsular Bend on the Rotational Stability Between Two Toric Intraocular Lenses
- Conditions
- Cataract
- First Posted Date
- 2024-11-27
- Last Posted Date
- 2024-11-27
- Lead Sponsor
- Wenzhou Medical University
- Target Recruit Count
- 68
- Registration Number
- NCT06707740
- Locations
- 🇨🇳
Ophthalmology and Optometry Hospital, Wenzhou, Wenzhou, China
Quantitative Assessment of Lid Margin Vascularity Using SS-OCTA
- Conditions
- Lid Margin Blood Flow DensitySs-octaMGD
- First Posted Date
- 2023-10-19
- Last Posted Date
- 2023-10-19
- Lead Sponsor
- Wenzhou Medical University
- Target Recruit Count
- 150
- Registration Number
- NCT06091722
- Prev
- 1
- 2
- 3
- 4
- 5
- 19
- Next
News
FDA Grants Orphan Drug Designation to China-Developed ApDC for Uveal Melanoma
An Aptamer Drug Conjugate (ApDC) developed by Chinese researchers has received orphan drug designation from the FDA for uveal melanoma treatment.